| Seizures, Focal
Afinitor vs Vimpat
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Afinitor vs Vimpat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimpat has a higher rate of injection site reactions vs Afinitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimpat but not Afinitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afinitor
Vimpat
At A Glance
Oral
Daily
mTOR inhibitor
Oral; IV infusion
Twice daily
Sodium channel modulator
Indications
- Hormone receptor positive breast cancer
- Neuroendocrine tumor of pancreas
- Gastro-enteropancreatic neuroendocrine tumor
- Renal Cell Carcinoma
- Angiomyolipoma of kidney
- Subependymal Giant Cell Astrocytoma
- Seizures, Focal
- Seizures, Focal
- Idiopathic generalized epilepsy
Dosing
Hormone receptor positive breast cancer 10 mg orally once daily in combination with exemestane until disease progression or unacceptable toxicity.
Neuroendocrine tumor of pancreas, Gastro-enteropancreatic neuroendocrine tumor 10 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 10 mg orally once daily until disease progression or unacceptable toxicity.
Angiomyolipoma of kidney 10 mg orally once daily until disease progression or unacceptable toxicity.
Subependymal Giant Cell Astrocytoma Starting dose 4.5 mg/m2 orally once daily (AFINITOR or AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Starting dose 5 mg/m2 orally once daily (AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Monotherapy (adults >=17 years): initiate 100 mg twice daily, maintenance 150-200 mg twice daily (300-400 mg/day); adjunctive therapy (adults): initiate 50 mg twice daily, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients 1 month to <17 years: weight-based dosing twice daily; max 200 mg twice daily; IV infusion available at same dose when oral temporarily not feasible.
Idiopathic generalized epilepsy Adjunctive therapy only for patients 4 years of age and older; adults: initiate 50 mg twice daily, titrate by 50 mg twice daily weekly, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients: weight-based dosing twice daily.
Contraindications
- Clinically significant hypersensitivity to everolimus or other rapamycin derivatives
—
Adverse Reactions
Most common (>=30%) Stomatitis, infections, rash, fatigue, diarrhea, decreased appetite.
Serious Non-infectious pneumonitis, infections, severe hypersensitivity reactions, angioedema, stomatitis, renal failure, impaired wound healing, metabolic disorders (hyperglycemia, dyslipidemia), myelosuppression, radiation sensitization and recall.
Postmarketing Thrombotic microangiopathy, cardiac failure (including with pulmonary hypertension), acute pancreatitis, cholecystitis, cholelithiasis, sepsis, reflex sympathetic dystrophy, arterial thrombotic events, lymphedema, radiation sensitization and recall.
Most common (>=2%) dizziness, headache, nausea, diplopia, ataxia, somnolence, vomiting, fatigue, blurred vision, vertigo, tremor, nystagmus, balance disorder
Serious suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, DRESS/multiorgan hypersensitivity reactions
Postmarketing agranulocytosis, aggression, agitation, hallucination, insomnia, psychotic disorder, angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis, dyskinesia, new or worsening seizures
Pharmacology
Everolimus is an mTOR inhibitor that binds the intracellular protein FKBP-12 to form an inhibitory complex with mTORC1, suppressing downstream effectors (S6K1, 4E-BP1) involved in protein synthesis, cell proliferation, and angiogenesis, and reducing HIF-1 and VEGF expression; mTOR pathway dysregulation occurs in several human cancers and in tuberous sclerosis complex.
Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing; it is a functionalized amino acid antiepileptic agent.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afinitor
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Vimpat
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Afinitor
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Vimpat
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Afinitor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Vimpat
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Afinitor.
No savings programs available for Vimpat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfinitorView full Afinitor profile
VimpatView full Vimpat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.